AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
We hypothesize that AndroGel may offer some relief to subjects with low or borderline
testosterone levels who suffer from depression and have failed to respond to a trial of a
standard antidepressant.
During this nine week, outpatient, double-blind study, male subjects between the ages of 30
and 65 years with treatment-refractory depression and low or borderline low testosterone
levels will be treated with either AndroGel or placebo. Following this nine week,
double-blind phase, eligible subjects will have the option to continue into a six month,
open-label phase during which time all subjects will receive the AndroGel patch.